Most primary care physicians don't prescribe peptides — not because the evidence is poor, but because the field isn't in their training. This guide tells you exactly where to look, what to ask, and how to tell a thorough prescriber from a rubber-stamp operation.
Peptide prescribing sits at the intersection of three medical knowledge gaps that even excellent clinicians may not have crossed: endocrinology training focused on deficiency treatment (not optimization), pharmacology training that didn't include synthetic peptide analogs, and a regulatory landscape that most physicians find more confusing than illuminating.
When your primary care physician says "I don't know enough about peptides to prescribe them," they are being appropriately honest — not signaling that the evidence doesn't support consideration. The peer-reviewed literature on GH secretagogues, BPC-157, and GHK-Cu exists and is accessible. It simply isn't taught in standard medical education. This is why specialty is a better search signal than general physician quality when looking for a peptide-informed prescriber.
The demand for peptide prescriptions has created a second problem: telemedicine platforms that function as prescription mills, providing minimal evaluation before issuing protocols. The goal is not simply finding someone who will prescribe — it is finding someone who will evaluate you appropriately and prescribe only what is indicated. A physician who orders labs, reviews your history, and adjusts your protocol based on results is providing fundamentally different care from one who approves a standard protocol from a 5-minute intake form.
Certain specialties have dramatically higher concentrations of peptide-knowledgeable physicians — driven by their training focus, patient demographics, and the continuing education ecosystems surrounding their field.
Physicians who have completed A4M (American Academy of Anti-Aging Medicine) fellowship or board certification are immersed in the optimization and research compound literature. This is where the densest concentration of peptide experience resides.
IFM-trained physicians operate within a "root cause" optimization framework that aligns well with peptide research. Many have peptide familiarity through their CME ecosystem, though the depth varies significantly by individual physician.
Sports medicine physicians working with elite athletes or high-performance populations may have peptide experience, particularly with recovery-oriented compounds (BPC-157, TB-500 — acknowledging 2024 compounding restrictions) and GH-axis optimization. WADA familiarity is a prerequisite for athlete work.
DPC and concierge physicians have time for the longer consultations that peptide evaluation requires, and many have expanded into longevity medicine as a service differentiator. The variation is enormous — ask specifically about peptide experience before booking.
Endocrinologists are the most relevant specialty by training for GH-axis peptides, but most operate within a disease-management rather than optimization framework. Some will prescribe Sermorelin or Tesamorelin for documented deficiency; few prescribe for optimization in otherwise healthy adults.
TRT clinics and hormone optimization practices frequently offer peptide protocols alongside testosterone therapy. Quality varies dramatically — from excellent physician-led practices to non-physician operations that should be evaluated with significant scrutiny. Look for MD or DO credentials on the prescribing provider.
The American Academy of Anti-Aging Medicine maintains a searchable directory of A4M-certified and member physicians. Filter by specialty and location. Certification indicates engagement with the anti-aging CME ecosystem — peptide familiarity is likely though not guaranteed.
The Institute for Functional Medicine's provider search lists IFM-trained physicians. More variable than A4M for peptide knowledge specifically — call the practice and ask directly about peptide protocols before booking.
Multiple platforms have built clinical infrastructure specifically for peptide and hormone protocols. Joi Health, Revive MD, and similar longevity-focused telehealth companies employ physicians specifically selected for this expertise. Evaluate the consultation depth, not just availability.
503A compounding pharmacies that compound peptides maintain relationships with prescribing physicians and can often refer patients to local or telehealth providers who work with their pharmacy. Call the pharmacy first — they know which physicians in your area have the relevant expertise.
Physicians who present at or attend A4M, AMMG (Age Management Medicine Group), or SSIEM conferences are embedded in the academic community driving this field. Conference websites sometimes list faculty with contact information, and many offer direct-to-patient services.
Online communities focused on longevity and peptide research often maintain informal physician referral lists sourced from member experience. These carry no formal quality guarantee but represent real-world experience. Treat as a starting point for research, not a vetted directory.
A prepared, informed patient gets better care. Arriving with relevant labs already completed, a clear list of goals, and familiarity with your own medical history positions you for a substantive first consultation rather than a basic intake session.
These questions serve a dual purpose: they surface important clinical information and they signal whether your physician has genuine depth in this area or is prescribing from a standardized protocol with minimal individualization.
Reveals whether the physician has an individualized baseline approach or a generic protocol regardless of patient status.
GH secretagogues elevate IGF-1. A physician without a monitoring plan is not practicing safe prescribing in this category.
Tests whether the physician has thought through safety thresholds, not just initiation criteria.
Reveals the physician's supply chain awareness and whether they're working with quality-verified pharmacies.
Tests individualization. A physician prescribing the same protocol to everyone regardless of history is not evaluating you specifically.
Calibrates the physician's honesty about evidence quality vs. optimistic overclaiming.
Some behaviors are consistent with inadequate prescribing practices — not merely individual style. These are the signs that should prompt you to seek a different provider before starting any protocol.
No responsible prescriber initiates GH-axis peptides without at minimum an IGF-1 baseline. A physician who prescribes without labs has no ability to dose appropriately or detect adverse changes.
Every pharmacologically active compound has risks. A physician who characterizes any peptide protocol as having no risks is either uninformed or being deliberately misleading. Responsible prescribers discuss theoretical risks — even if the evidence suggests those risks are low.
If the physician offers the same protocol (same compounds, same doses, same cycles) to every patient without history-dependent adjustment, they are not evaluating you — they are processing orders. Individual variation in IGF-1 status, metabolism, and goals demands individualized protocols.
Any protocol involving GH-axis compounds requires IGF-1 monitoring at minimum. A prescriber without a monitoring plan is not managing your care — they are initiating it and abandoning oversight. Lab rechecks and dose adjustments should be built into the protocol from the start.
Prescription peptides legally require a licensed physician (MD or DO) prescription in most US states. Nurse practitioners and physician assistants can prescribe in some states under physician supervision, but it should be transparent. An entirely non-physician telehealth operation prescribing without physician oversight is a licensing violation, not just a quality concern.
A physician who recommends 6–8 peptides simultaneously at a first visit — particularly without a completed lab workup — is likely operating from a revenue-optimization rather than evidence-optimization framework. Start with one or two compounds appropriate for your specific goals; expand based on response.
IGF-1, thyroid panel, metabolic panel, hormone levels — before writing any prescription. Uses lab results to individualize protocol rather than applying a standard template.
Reviews your history for hormone-sensitive malignancy, insulin resistance, active cancer, and other factors that would modify compound selection or dose. Doesn't skip the safety conversation.
Sets expectations for follow-up labs, specific values to track, dose adjustment criteria, and discontinuation thresholds before initiating any protocol.
Frames the evidence as it is — promising but often preclinical or limited in human trials — rather than overselling or dismissing. Intellectual honesty about evidence gaps is a quality signal.
Has established relationships with licensed compounding pharmacies and can explain the quality assurance processes their pharmacy uses. Not just "I work with a compounding pharmacy."
Recommends beginning with one or two compounds at lower-end doses, reassessing at 4–8 weeks, and expanding based on response and labs — rather than a maximal protocol from day one.
These are the baseline clinical steps that should occur before a responsible physician writes any peptide prescription. If several of these are absent from your appointment, raise them directly before accepting any prescription. A physician who completes this standard has evaluated you as a patient. A physician who skips several steps has evaluated a demographic category.
You don't need to interrogate your physician or arrive with a clipboard. But if your first appointment was 10 minutes on a form with no lab review, no history discussion, and a prescription appeared — that is not a clinical evaluation. The items below are the minimum a thoughtful prescriber would complete before writing any GH-axis or tissue-repair peptide protocol.
For any GH-axis compound (CJC-1295, Ipamorelin, Sermorelin, Tesamorelin), a fasting IGF-1 is the minimum baseline. It establishes where you are before treatment and sets the safety ceiling for dose escalation.
Comprehensive metabolic panel plus fasting insulin and glucose. GH secretagogues can transiently worsen insulin sensitivity. A physician who doesn't screen for pre-existing insulin resistance is prescribing without knowing a key risk modifier.
TSH at minimum; free T3 and free T4 preferred. Hypothyroidism blunts GH axis response and affects recovery. Treating a GH secretagogue protocol in a patient with undiagnosed thyroid dysfunction produces suboptimal results and obscures the cause.
Total testosterone, free testosterone, SHBG (men); estradiol, FSH, LH (women). Hormone status shapes which compounds are appropriate, what baseline to expect for body composition response, and flags concurrent deficiencies that affect outcomes.
Active malignancy is a contraindication for IGF-1-elevating compounds. Prior hormone-sensitive cancers (prostate, breast) warrant explicit discussion before any GH-axis protocol. This isn't a form checkbox — it's a clinical conversation about relative vs. absolute contraindication.
A form signature is not informed consent. The physician should explain: (1) the mechanism of each proposed compound, (2) the regulatory status, (3) the monitoring plan, (4) discontinuation criteria, and (5) symptoms to report immediately. Verbal explanation is the standard — the form documents it.
Your protocol — compound names, doses, administration route, injection timing, cycle structure — should be documented in your chart or provided to you in writing. This creates a clinical record and ensures the prescription matches the discussion. Request a copy.
For GH-axis compounds: IGF-1 recheck at 4–8 weeks is standard. The recheck appointment should be booked, not left open-ended. "We'll see how you feel" is not a monitoring plan for a compound that acts through a quantifiable biomarker.
Who do you call if you have a reaction, an injection site concern, or a question about your protocol between appointments? A patient portal, nurse line, or secure messaging channel should be established before you leave. Accessibility for clinical questions is not a luxury — it's a safety requirement.
Once a physician proposes a protocol, here are the clinical logic checks to apply — not to second-guess your physician, but to ensure the proposal reflects individualized thinking rather than a template applied without adaptation.
A sound protocol proposal connects your labs to your goals, names specific compounds with clinical rationale, identifies a verified pharmacy, specifies a monitoring schedule with a specific follow-up timeline, and uses language calibrated to the actual evidence base. If the proposal does all of these things and you feel genuinely evaluated — that's the standard of care working as it should.
Telemedicine has fundamentally changed access to peptide prescriptions. For a discipline where physician expertise matters more than in-person examination findings, telehealth is often an appropriate — and sometimes better — care delivery model.
Ask: (1) What is the consultation format — synchronous video, or asynchronous form review? (2) Who reviews the labs — a physician or an NP/PA? (3) What lab panel do you order before prescribing? (4) Is there a dedicated physician who will manage my case, or a rotation? (5) Do you prescribe from a 503A or 503B pharmacy — and which one? A platform that cannot answer these clearly is not operating at the standard of care this field requires.
Physician-supervised peptide protocols are essentially universally out-of-pocket expenses. Understanding the full cost picture — consultation, labs, and compounds — allows for informed planning.
| Cost Component | In-Person Specialist | Telehealth Platform | Notes |
|---|---|---|---|
| Initial consultation | $300–800 | $100–300 | Varies significantly by physician. Concierge practices may include initial labs. |
| Baseline lab panel | $150–400 | $150–400 | IGF-1 + comprehensive panel. Some insurance covers routine labs. Direct lab ordering (LabCorp/Quest) often cheaper than physician-ordered. |
| Follow-up labs (quarterly) | $80–200 | $80–200 | IGF-1 recheck + relevant markers. Budget for 2–4 lab draws/year on an active protocol. |
| CJC-1295 + Ipamorelin (monthly) | $150–350/month (503B pharmacy) | Most commonly prescribed GH secretagogue combination. 503B typically higher than 503A. | |
| Sermorelin (monthly) | $100–250/month | Lower cost than CJC+Ipa; approved compound with broader compounding availability. | |
| GHK-Cu peptide (monthly) | $80–150/month (topical) | Topical formulation; lower cost than injectable compounds. Some 503A pharmacies compound injectable form. | |
| Follow-up consultations | $150–400/visit | $50–150/visit | Budget for at minimum 2–3 follow-up consultations in the first year of a new protocol. |
| Annual total estimate | ~$4,000–10,000 | ~$2,500–5,000 | Highly variable by protocol complexity and compound selection. Single-compound protocols significantly less. |
If a telemedicine platform is offering complete peptide consultations and compounds at dramatically below-market pricing — significantly under $200/month all-in — the economic model of paying for appropriate physician time, pharmacy quality assurance, and compound sourcing doesn't support that price point. Price is not a reliable quality indicator in medicine, but extreme undercutting in a market where quality requires real cost is worth scrutinizing.
Technically yes — any licensed physician can prescribe compounded peptides off-label. Practically, most primary care physicians don't feel comfortable doing so because it's outside their training and may fall outside their scope of comfort with off-label prescribing. A better strategy than asking your PCP to prescribe something unfamiliar to them is to seek a physician who has built expertise in this area — they'll prescribe more confidently, monitor more appropriately, and provide better-informed guidance on compound selection and dosing. If your PCP is willing to learn alongside you, that's a different situation — some excellent generalists are genuinely curious and will engage seriously with the literature.
For telemedicine peptide prescribing, the physician must be licensed in the state where the patient is located at the time of the consultation — the same rule that governs all telemedicine prescribing. Many telemedicine platforms are licensed in multiple states to accommodate this. Some states have more restrictive telemedicine prescribing laws; your state's medical board website lists current telehealth prescribing regulations if you want to verify your specific state's requirements.
NPs and PAs can prescribe in most states under physician supervision protocols (the specifics vary by state — some allow independent NP prescribing; others require physician oversight). The prescribing credential matters less than the clinical expertise and the supervision structure. What matters is that someone with genuine pharmacological knowledge of peptides — MD, DO, or a highly specialized NP/PA — is making the prescribing decision, not applying a template. At telehealth platforms, always ask whether a physician reviews each prescription even if the initial consultation is with an NP or PA.
This is actually the most clinically responsible approach for people using research compounds — keeping their physician in the loop even without a formal prescription relationship. Many physicians who don't prescribe peptides will still help you monitor labs if you're transparent about what you're using. Bring your research compound's COA, explain what you're taking and why, and ask about relevant safety labs. A physician who refuses to engage with this information even for monitoring purposes is prioritizing comfort over patient care. If you encounter that, consider adding a longevity-focused physician as a consultant even if your primary care relationship remains with someone else.
The questions in the section above are the most reliable signal. A knowledgeable prescriber will have nuanced answers about lab monitoring, contraindications, and evidence quality — not just enthusiasm for the compounds. Ask about the mechanism of action of the compound they're recommending and what the evidence base looks like. Ask what the biggest risks are and what would cause them to discontinue the protocol. Answers that reflect genuine clinical thinking — with appropriate uncertainty and caution — are more trustworthy than perfectly confident answers for a field with significant evidence gaps.